Deniz Tschammler advises German and international companies on all regulatory and compliance issues throughout the life cycle of drugs and medical devices as well as in the area of medical technology. He focuses on complex legal issues in the context of the ongoing digitization of the health sector, for example at the interface of health and data protection laws.
Deniz provides comprehensive advice on drug and medical device law, including clinical trials, marketing authorization and manufacturing, market access and reimbursement as well as advertising and distribution. He has particular expertise in social, competition and other administrative law matters. In particular, he provides background advice in the area of commercial criminal law, including fraud and anti-bribery law, and in internal investigations.
Deniz is an expert in the establishment and refinement of internal compliance organizations, particularly with respect to anti-corruption and data protection issues.
Deniz is the author of numerous articles in the field of health and pharmaceutical law.
Research Group on Pharmaceutical Law at the Philipps University of Marburg, Promotion Circle member
German-American Lawyers’ Association, member
University of St. Gallen, Executive MBA, 2019 to 2021
King’s College London, LLM, 2013
Higher Regional Court of Wiesbaden, Second State Examination, 2012
Philipps University of Marburg, PhD, 2011
Goethe University of Frankfurt, First State Examination, 2008
Universities of Frankfurt and Lyon, Diploma in French Law, 2007
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.